Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 54Lymphoma 44Lymphoma, Large B-Cell, Diffuse 35Lymphoma, Follicular 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Lymphoma, Non-Hodgkin 22Multiple Myeloma 19Leukemia 17Burkitt Lymphoma 13Hodgkin Disease 12Lymphoma, Mantle-Cell 10Neoplasms 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, B-Cell, Marginal Zone 8Lymphoma, Large-Cell, Anaplastic 7Neoplasms, Plasma Cell 6Neoplasm Metastasis 6Lymphoma, T-Cell, Peripheral 6Recurrence 4Leukemia, Lymphocytic, Chronic, B-Cell 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pain 3Lymphoma, B-Cell 3Prostatic Neoplasms, Castration-Resistant 2Prostate Cancer Metastatic 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Myasthenia Gravis 2Leukemia, Biphenotypic, Acute 2Disease 2

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Prednisone × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡